Kidney Cancer
Kidney cancer, also known as renal cancer, is characterized by abnormal cell growth and replication in the kidneys, leading to symptoms such as blood in the urine, a lump in the abdomen, back pain, fever, weight loss, and tiredness, and may spread to the lungs or brain if untreated.
Health Outcomes
- Delayed Tumor Onset
- Enhanced Anticancer Capacity
- Enhanced Cell Viability
- Enhanced Natural Killer Cell Activity
- Enhanced Natural Killer Cell Tumor Killing Activity
- Improved CT Imaging
- Improved Effectiveness in Cancer Treatment
- Improved Histopathological Indicators
- Improved Natural Killer Cell Activation
- Improved Natural Killer Cell Activity
- Improved Natural Killer Cell Tumoricidal Activity
- Improved Progression-free Survival
- Improved Response to Immune Checkpoint Inhibitor Therapy
- Improved Response to PD-1 Immunotherapy
- Improved Survival Capacity
- Improved Survival Rate
- Inactivated Other Receptor Tyrosine Kinase Activity
- Increased Anti-Tumor Activity
- Increased Anticancer Activity
- Increased Cell Death
- Increased Survival Rate
- Increased Telomere Length
- Increased mTORC1 Activation
- Inhibited Epithelial-Mesenchymal Transition
- Inhibited PI3K/AKT Pathway
- Overall Treatment Success
- Reduced Allograft Rejection
- Reduced Cancer Risk
- Reduced Epithelial-Mesenchymal Transition
- Reduced Fumonisin B1 Levels
- Reduced Graft Rejection
- Reduced Pulmonary Metastasis
- Reduced Renal Cell Cancer Incidence
- Reduced Thioredoxin-Binding Protein Level
- Reduced Thioredoxin-Binding Protein-2 Level
- Reduced Tumor Incidence
- Reduced Tumor Stage
- Targeted Tumor Reduction
- Unchanged Survival Rate